The Journal of Allergy and Clinical Immunology
Volume 122, Issue 3 , Pages 574-580 , September 2008

Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases

  • Mariana C. Castells, MD, PhD

      Affiliations

    • Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass
    • Corresponding Author InformationReprint requests: Mariana C. Castells, MD, PhD, One Jimmy Fund Way, Smith Building, Room 626D, Boston, MA 02115.
    • These authors contributed equally to this work.
    • ,
  • Nichole M. Tennant, BA

      Affiliations

    • Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass
    • These authors contributed equally to this work.
    • ,
  • David E. Sloane, MD

      Affiliations

    • Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass
    • These authors contributed equally to this work.
    • ,
  • F. Ida Hsu, MD

      Affiliations

    • Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass
    • These authors contributed equally to this work.
    • ,
  • Nora A. Barrett, MD

      Affiliations

    • Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass
    • ,
  • David I. Hong, MD

      Affiliations

    • Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Tanya M. Laidlaw, MD

      Affiliations

    • Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Henry J. Legere, MD

      Affiliations

    • Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Samridhi N. Nallamshetty, MD

      Affiliations

    • Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Ross I. Palis, MD

      Affiliations

    • Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Jayanti J. Rao, MD

      Affiliations

    • Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Suzanne T. Berlin, DO

      Affiliations

    • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Mass
    • ,
  • Susana M. Campos, MD

      Affiliations

    • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Mass
    • ,
  • Ursula A. Matulonis, MD

      Affiliations

    • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Mass

Received 14 December 2007 ,Revised 27 February 2008 ,Accepted 29 February 2008.

  • Image Result

    Frequency of symptoms and signs during initial HSRs.

    Frequency of symptoms and signs during initial HSRs.

  • Image Result

    A, Number and severity of reactions during desensitization. A mild reaction was defined as absence of chest pain, changes in blood pressure, dyspnea, oxygen, desaturation, or throat tightness. A sever

    A, Number and severity of reactions during desensitization. A mild reaction was defined as absence of chest pain, changes in blood pressure, dyspnea, oxygen, desaturation, or throat tightness. A severe reaction included 1 of these. B, Desensitization step at which reactions occurred (total number of reactions = 180). C, Desensitization course at which reactions recurred (total number of reactions = 135 [111 mild and 24 severe]).

 Supported by the Ovations for the Cure Desensitization Program.

 Disclosure of potential conflict of interest: D. E. Sloane has received honoraria from Genentech. F. I. Hsu has served as a coinvestigator for Dyax Corporation and has received a research grant from the American Academy of Allergy, Asthma & Immunology. N. A. Barrett has served as a coinvestigator for the National Institutes of Health and has served as a primary investigator for the American Academy of Allergy, Asthma & Immunology and Altana. D. I. Hong and T. M. Laidlaw have received training grant salary from the National Institutes of Health. S. N. Nallamshetty has received training grant salary from the National Institutes of Health and research grants from the American Academy of Allergy, Asthma & Immunology and GlaxoSmithKline. S. M. Campos has served as a research consultant for Genentech and has received research support from Genentech, Novartis, and Ortho-Biotechnology. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(08)00762-8

doi: 10.1016/j.jaci.2008.02.044

The Journal of Allergy and Clinical Immunology
Volume 122, Issue 3 , Pages 574-580 , September 2008

Article Tools

* Image Usage & Resolution